Urinalysis Market

The urinalysis market is valued at an estimated USD 4.3 billion in 2024 and is projected to reach USD 6.8 billion by 2029 at a CAGR of 9.6% during the forecast period. Growth in the urinalysis market is mainly driven by factors such as the increasing burden of urinary tract infections (UTIs), diabetes, and kidney & liver diseases and the increasing adoption of PoC tests.

The key players in this market are Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health (US), Abbott (US), Danaher (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), QuidelOrtho Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), EKF Diagnostics Holdings plc (UK), ARKRAY, Inc. (Japan), ACON Laboratories, Inc. (US), 77 Elektronika Kft. (Hungary), URIT Medical Electronic Co., Ltd. (China), DIRUI INDUSTRIAL CO., LTD. (China), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BIOBASE Group (China), Erba Mannheim (UK), Alphatec Scientific E.I.R.L. (Peru), Teco Diagnostics (US), Analyticon Biotechnologies GmbH (Germany), Bioway Biological Technology Co., Ltd. (China), High Technology, Inc. (US), Agappe Diagnostics Ltd. (India), TOYOBO CO., LTD. (Japan), DIALAB GmbH (Austria), Quantimetrix (US), BioCare Corporation (Taiwan), Randox Laboratories Ltd. (Ireland), PZ Cormay S.A. (Poland), YD Diagnostics (South Korea), CONTEC MEDICAL SYSTEMS CO., LTD. (China), and Biopanda Reagents Ltd. (UK).

To know about the assumptions considered for the study download the pdf brochure

In 2023, Siemens Healthineers AG (Germany) emerged as the top player in the urinalysis market. The company maintains a robust presence worldwide and attributes its market leadership to its extensive product portfolio. Siemens Healthineers prioritizes innovation through significant investments in research and development. To further reinforce its market position, the company adopts strategic measures such as partnerships, collaborations, and expansions. By partnering with new businesses, the company enhances its existing segments and incorporates cutting-edge technologies and products into its portfolio.

In 2023, F. Hoffmann-La Roche Ltd. (Switzerland) commanded a substantial market share within the urinalysis market. Roche is a major player in the biochemical urinalysis market due to its vast product portfolio of urine analyzers and test strips. The company focuses on innovation to maintain its market share and significantly invests in R&D activities. This investment is used to develop new and innovative products. The company’s market position can be attributed to its strong sales and distribution network worldwide, enabling it to market its products in various countries effectively.

In 2023, Cardinal Health (US) held a prominent position in the urinalysis market. The company derives a significant portion of its revenue from the US markets. It focuses on expanding its self-manufacturing capacity and sourcing capabilities while optimizing its end-to-end global supply chain. For instance, in April 2023, the company announced the opening of two new distribution centers in Central Ohio that will support the company’s Medical Segment, focusing on its US Medical Products and Distribution (USMPD) and At-home Solutions businesses. By implementing cost-saving initiatives, especially within its global manufacturing and supply chain, the company achieves substantial benefits throughout the year. Committed to long-term growth, the company pursues both organic growth opportunities and strategic investments to diversify its capabilities and create lasting value.

Related Reports:

Urinalysis Market by Product (Consumables (Pregnancy & Fertility Kits, Dipsticks, Disposable, Reagents), Instruments (Automated, Semi-automated, PoC Analyzers)), Test Type (Biochemical, Sediment), Application (UTI, Diabetes) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]